Overview: NGS Alexander Disease Sequencing TestIntroduction: The NGS Alexander Disease Sequencing Test sequences genes to diagnose Alexander disease, causing seizures or developmental delays. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Alexander disease.
Other Names: Alexander Disease Assay, GFAP Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Alexander disease sequencing began in the 2000s with leukodystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose Alexander disease, guides treatment, and evaluates patients with seizures or developmental delays.
Test Parameters: 1. Alexander Disease Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of seizures, developmental delays, or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document seizures, developmental delays, macrocephaly, or family history of leukodystrophies. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, Alexander disease implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze Alexander disease genes (e.g., GFAP). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Alexander disease diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm Alexander disease, guiding supportive care or genetic counseling. Negative results may require broader sequencing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, EEG, or CSF analysis to confirm Alexander disease diagnosis.
Test Limitations: Not all Alexander disease cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Leukodystrophy Guidelines, 2023; Neurology, Brenner M, 2022.
